Table 1 Clinical features of the CCA patients (n = 57) according to miR-124 expression grouping
From: miR-124 targets GATA6 to suppress cholangiocarcinoma cell invasion and metastasis
Features | MiR-124 Expression | P valueb | |
|---|---|---|---|
High (N = 29) | Low (N = 28) | ||
Age | 55.9 ± 9.7 | 56.0 ± 10.8 | 0.969 |
Gender | 0.516 | ||
Male | 18 (62%) | 15 (54%) | |
Female | 11 (38%) | 13 (46%) | |
Location | 0.682 | ||
Intrahepatic | 4 (14%) | 6 (21%) | |
Extrahepatic | 25 (86%) | 22 (79%) | |
Histological Grade | 0.580 | ||
G1 | 6 (21%) | 4 (14%) | |
G2 | 21 (72%) | 20 (71%) | |
G3 | 2 (7%) | 4 (14%) | |
T classificationa | 0.741 | ||
T1 | 7 (10%) | 4 (33%) | |
T2 | 9 (44%) | 8 (27%) | |
T3 | 8 (28%) | 9 (25%) | |
T4 | 5 (18%) | 7 (15%) | |
Lymphnode involvement | 0.012c | ||
Yes | 8 (28%) | 17 (61%) | |
No | 21 (72%) | 11 (39%) | |
Distant metastasis | 0.125 | ||
Yes | 6 (21%) | 11 (39%) | |
No | 23 (79%) | 17 (61%) | |